Personalis, Inc. (PSNL) News
Filter PSNL News Items
PSNL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PSNL News Highlights
- PSNL's 30 day story count now stands at 2.
- Over the past 14 days, the trend for PSNL's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest PSNL News From Around the Web
Below are the latest news stories about PERSONALIS INC that investors may wish to consider to help them evaluate PSNL as an investment opportunity.
Even With A 37% Surge, Cautious Investors Are Not Rewarding Personalis, Inc.'s (NASDAQ:PSNL) Performance CompletelyPersonalis, Inc. ( NASDAQ:PSNL ) shares have had a really impressive month, gaining 37% after a shaky period... |
Personalis Extends Cash Position Into 2026, Provides Update on Key InitiativesFREMONT, Calif., December 04, 2023--Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), disclosed a reduction in headcount impacting approximately 20% of the company’s staff. By consolidating several functions for efficiency, this reduction is expected to reduce operating expenses by approximately $14 million annually. This action, along with the recently announced Tempus collaboration, is expected to extend the cash position of the company into 2026. |
Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer TestingFREMONT, Calif. & CHICAGO, November 28, 2023--Personalis, Inc., a leader in advanced genomics for precision oncology (Nasdaq: PSNL), and Tempus Labs, Inc., a leader in artificial intelligence and precision medicine, today announced a strategic collaboration to co-commercialize NeXT Personal® Dx, Personalis’ whole genome-based liquid biopsy laboratory developed test (LDT) for detection of molecular residual disease (MRD) and recurrence in cancer. NeXT Personal Dx is a leap forward in tumor-inform |
Meet the biotech company Cathie Wood bought half a million shares of this monthCathie Wood founded Ark Invest in 2014 to provide investors exposure to what she calls "disruptive innovation," a strategy that encompasses artificial intelligence, energy storage, blockchain technology, robotics and gene editing. While Ark's flagship Innovation ETF is largely exposed to Wood's chosen AI and cryptocurrency plays, Ark has invested plenty of capital into a variety of biotech firms across its funds. |
Personalis, Inc. (NASDAQ:PSNL) Q3 2023 Earnings Call TranscriptPersonalis, Inc. (NASDAQ:PSNL) Q3 2023 Earnings Call Transcript November 7, 2023 Personalis, Inc. beats earnings expectations. Reported EPS is $-0.48, expectations were $-0.54. Operator: Good afternoon and welcome to Personalis Third Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode. [Operator instructions] After today’s prepared remarks there will be an opportunity […] |
Personalis Reports Third Quarter 2023 Financial ResultsFREMONT, Calif., November 07, 2023--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2023 and provided recent business highlights. |
Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in CancerFREMONT, Calif., October 26, 2023--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today the launch of the Early Access Program for NeXT Personal Dx, a tumor-informed, whole genome-based liquid biopsy laboratory developed test (LDT) for detection of molecular residual disease (MRD) and recurrence in cancer. Designed to help oncologists detect cancer recurrence earlier and aid in treatment decision-making, NeXT Personal Dx is poised to reshape the |
Personalis to Announce Third Quarter 2023 Financial ResultsFREMONT, Calif., October 24, 2023--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2023 financial results on Tuesday, November 7, 2023. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. |
Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD TechnologyFREMONT, Calif., October 21, 2023--Personalis, Inc. (Nasdaq: PSNL), a leader in precision oncology, today announced the presentation of initial findings from its work with the groundbreaking TRACERx lung cancer study, marking a substantial advancement in lung cancer circulating tumor DNA (ctDNA) detection and management. The Personalis NeXT Personal cancer assay, created to detect and monitor residual and recurrent disease (MRD), demonstrated significantly improved detection rates for early-stag |
Personalis Announces Late-Breaking NeXT Personal Abstract and Proffered Paper Presentation at ESMO 2023FREMONT, Calif., October 19, 2023--Personalis, Inc. (Nasdaq: PSNL), a leader in precision oncology, today announced that a late-breaking abstract featuring data for the company’s NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection, has been accepted and selected for a proffered paper presentation at the 2023 European Society for Medical Oncology (ESMO) Congress, on October 21 in Madrid, Spain. |